Brief: Lee's Pharma's Unit Got Breakthrough Therapy Designation By NMPA For Oncology Product
09/02/2021 14:41
Feb 9 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* UNIT GRANTED BREAKTHROUGH THERAPY DESIGNATION BY NMPA FOR
ANTI-PD-L1 MONOCLONAL ANTIBODY, SOCAZOLIMAB
Source text for Eikon: ID:nHKS21GtNf
Further company coverage: 0950.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lee's Pharmaceutical Holdings
See all newsHong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product sales
Brief: Lee's Pharmaceutical Expects H1 Net Profit Of HK$85 Million-HK$95 Million
Brief: Lee's Pharmaceutical Says Investigational New Drug Application For ADC Project ZK2401 Accepted By NMPA
Brief: Ashlins Pharmaceuticals And Lee's Pharm Announce Exclusive License And Supply Agreement Valued At Up To $31 Million
Brief: Lee's Pharmaceutical Says Entered Licensing Agreement With Ashlins Ocular Pharmaceuticals